Clinical outcomes of venetoclax combined with hypomethylating agents <i>versus</i> hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromes.

Haematologica · 2026 · PMC13231094 · PMID 41504247

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

a trend toward significanceP =0.07so close (0.05 < p ≤ 0.1)

For OS censored at allo-HCT, overall response rate demonstrated a trend toward significance (HR=0.48; 95% CI: 0.22-1.07; P =0.07), whereas CR was not independently associated with survival (HR=0.54; 95% CI: 0.19-1.49; P =0.23).

also in 2,517 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Clinical outcomes of venetoclax combined with hypomethylating agents &lt;i&gt;versus&lt;/i&gt; hypomethylating agents alone in &lt;i&gt;TP53&lt;/i&gt;-mutated myelodysplastic syndromes.

The sentences

Clinical outcomes of venetoclax combined with hypomethylating agents <i>versus</i> hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromes.